

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Pembrolizumab Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road
HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance	: suspension
Colour	: Colorless to pale yellow
Odour	: No data available

May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

GHS Classification

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure : Category 2

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H373 May cause damage to organs through prolonged or re-

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Precautionary statements : peated exposure.

Prevention:
P203 Obtain, read and follow all safety instructions before use.
P260 Do not breathe mist or vapours.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

Response:
P318 IF exposed or concerned, get medical advice.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Not classified based on available information.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	≥ 1 -< 10
Pembrolizumab	1374853-91-4	≥ 1 -< 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

In case of eye contact	: Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
If swallowed	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x)
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Prevent spreading over a wide area (e.g. by containment or oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 49558-00027 Date of last issue: 2024/09/28
Date of first issue: 2015/01/23

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m ³	ACGIH
Pembrolizumab	1374853-91-4	TWA	450 µg/m ³ (OEB 2)	Internal

Engineering measures : Minimize workplace exposure concentrations.
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear the following personal protective equipment:
Safety glasses

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Colour : Colorless to pale yellow

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Odour	:	No data available
Odour Threshold	:	No data available
pH	:	5.5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Molecular weight : No data available

Particle characteristics
Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Components:

Sucrose:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative
-----------------------	---

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:

Pembrolizumab:

Reproductive toxicity - Assessment	: May damage the unborn child., Based on data from similar materials
------------------------------------	--

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Pembrolizumab:

Target Organs	: Immune system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Pembrolizumab:

Species	: Monkey
NOAEL	: 200 mg/kg
Application Route	: Intravenous
Exposure time	: 180 d
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 200 mg/kg
Application Route	: Intravenous
Exposure time	: 180 d
Remarks	: No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Experience with human exposure

Components:

Pembrolizumab:

Inhalation	: Target Organs: Immune system Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis Remarks: Damage to fetus possible
------------	--

12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Sucrose:

Partition coefficient: n-octanol/water	: Pow: < 1
--	------------

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number	: Not applicable
-----------	------------------

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : no

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Marine pollutant : no

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

logue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of determination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218) : Not listed

Hazardous Chemicals for Priority Management under SAWS : Not listed

Catalogue of Specially Controlled Hazardous Chemicals : Not listed

List of Explosive Precursors : Not listed

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export : Not listed

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import and Export : Not listed

List of Controlled Ozone Depleting Substances : Not listed

Environmental Protection Law

List of Priority Controlled Chemicals : Not listed

List of Key Controlled New Pollutants : Not listed

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

16. OTHER INFORMATION

Revision Date : 2025/04/14

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	49558-00027	Date of first issue: 2015/01/23

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN